In a report published Friday, BMO Capital Markets analyst Alex Arfaei reiterated an Outperform rating on Merck & Co. MRK, and raised the price target from $47.00 to $51.00.
In the report, Arfaei noted, “We are providing our 1Q13 preview and longer term outlook for Merck. Although Merck could come slightly below 1Q13 revenue expectations of $11.1Bn, it should meet or beat the Street's $0.78 EPS consensus, and its own $0.76-$0.78 guidance. We see some modest ($0.05) downside risk to current 2013 EPS guidance of $3.60-$3.70, primarily owing to unfavorable Fx (Venezuela and Japan). But we expect investors to quickly look past this and focus on a number of potentially positive catalysts in 2H13 for example, Suvorexant FDA advisory meeting in May followed by probable approval in summer, Anti-PD-1 data at ASCO (June), probable FDA approval for Bridion (fall), and phase-2 safety data for the potentially transformative BACE inhibitor MK-8931 in Alzheimer's disease.”
Merck & Co. closed on Thursday at $46.56.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in